Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD The second dose of Shingrix (recombinant zoster vaccine) may cause side effects that are worse than the first. The second dose is ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

SINGAPORE: The Ministry of Health (MOH) announced on Monday (Feb 10) that it will extend subsidies and MediSave usage for ...